150 related articles for article (PubMed ID: 36161375)
1. Integration of Universal Germline Genetic Testing for All New Breast Cancer Patients.
Culver JO; Freiberg Y; Ricker C; Comeaux JG; Chang EY; Banerjee V; Sturgeon D; Solomon I; Kagey J; Dobre MG; Carey J; Carr A; Cho S; Lu J; Kang IM; Patel K; Terando A; Ye JC; Li M; Lerman C; Spicer D; Nelson M
Ann Surg Oncol; 2023 Feb; 30(2):1017-1025. PubMed ID: 36161375
[TBL] [Abstract][Full Text] [Related]
2. Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy.
Dettwyler SA; Thull DL; McAuliffe PF; Steiman JG; Johnson RR; Diego EJ; Mai PL
Breast Cancer Res Treat; 2022 Jul; 194(2):393-401. PubMed ID: 35596825
[TBL] [Abstract][Full Text] [Related]
3. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
4. New germline BRCA2 gene variant in the Tuvinian Mongol breast cancer patients.
Gervas P; Klyuch B; Denisov E; Kiselev A; Molokov A; Pisareva L; Malinovskaya E; Choynzonov E; Cherdyntseva N
Mol Biol Rep; 2019 Oct; 46(5):5537-5541. PubMed ID: 31273614
[TBL] [Abstract][Full Text] [Related]
5. Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis.
Sandoval RL; Leite ACR; Barbalho DM; Assad DX; Barroso R; Polidorio N; Dos Anjos CH; de Miranda AD; Ferreira ACSM; Fernandes GDS; Achatz MI
PLoS One; 2021; 16(2):e0247363. PubMed ID: 33606809
[TBL] [Abstract][Full Text] [Related]
6. A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
Donenberg T; George S; Ali J; Bravo G; Hernandez K; Sookar N; Ashing KT; Narod SA; Akbari MR; Hurley J
Breast Cancer Res Treat; 2019 Apr; 174(2):469-477. PubMed ID: 30515680
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
8. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
Bednar EM; Oakley HD; Sun CC; Burke CC; Munsell MF; Westin SN; Lu KH
Gynecol Oncol; 2017 Aug; 146(2):399-404. PubMed ID: 28610746
[TBL] [Abstract][Full Text] [Related]
9. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
[TBL] [Abstract][Full Text] [Related]
10. Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.
Theobald KA; Susswein LR; Marshall ML; Roberts ME; Mester JL; Speyer D; Williams RNW; Knapke SC; Solomon SR; Murphy PD; Klein RT; Hruska KS; Solomon BD
Ann Surg Oncol; 2018 Nov; 25(12):3556-3562. PubMed ID: 30167906
[TBL] [Abstract][Full Text] [Related]
11. New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients.
Gervas P; Molokov A; Ivanova A; Panferova Y; Kiselev A; Chernyshova A; Pisareva L; Choynzonov E; Cherdyntseva N
Exp Oncol; 2021 Mar; 43(1):52-55. PubMed ID: 33785725
[TBL] [Abstract][Full Text] [Related]
12. BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.
Nilsson MP; Törngren T; Henriksson K; Kristoffersson U; Kvist A; Silfverberg B; Borg Å; Loman N
Breast Cancer Res Treat; 2018 Feb; 168(1):117-126. PubMed ID: 29164420
[TBL] [Abstract][Full Text] [Related]
13. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
[TBL] [Abstract][Full Text] [Related]
14. Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk-based testing of those older than 60 years.
Desai NV; Yadav S; Batalini F; Couch FJ; Tung NM
Cancer; 2021 Mar; 127(6):828-833. PubMed ID: 33146899
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families.
Haanpää M; Pylkäs K; Moilanen JS; Winqvist R
BMC Med Genet; 2013 Aug; 14():82. PubMed ID: 23941127
[TBL] [Abstract][Full Text] [Related]
16. Impact of Genetic Testing on Risk-Management Behavior of Black Breast Cancer Survivors: A Longitudinal, Observational Study.
Conley CC; Kasting ML; Augusto BM; Garcia JD; Cragun D; Gonzalez BD; Kim J; Ashing KT; Knott CL; Hughes-Halbert C; Pal T; Vadaparampil ST
Ann Surg Oncol; 2020 May; 27(5):1659-1670. PubMed ID: 31677107
[TBL] [Abstract][Full Text] [Related]
17. Gene Panel Testing in Hereditary Breast Cancer.
Rostami P; Zendehdel K; Shirkoohi R; Ebrahimi E; Ataei M; Imanian H; Najmabadi H; Akbari MR; Sanati MH
Arch Iran Med; 2020 Mar; 23(3):155-162. PubMed ID: 32126783
[TBL] [Abstract][Full Text] [Related]
18. Detection of germline variants in Brazilian breast cancer patients using multigene panel testing.
Guindalini RSC; Viana DV; Kitajima JPFW; Rocha VM; López RVM; Zheng Y; Freitas É; Monteiro FPM; Valim A; Schlesinger D; Kok F; Olopade OI; Folgueira MAAK
Sci Rep; 2022 Mar; 12(1):4190. PubMed ID: 35264596
[TBL] [Abstract][Full Text] [Related]
19. Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel.
Moran O; Nikitina D; Royer R; Poll A; Metcalfe K; Narod SA; Akbari MR; Kotsopoulos J
Breast Cancer Res Treat; 2017 Jan; 161(1):135-142. PubMed ID: 27798748
[TBL] [Abstract][Full Text] [Related]
20. Provider discussion of genetic counseling among high-risk Spanish-preferring Latina breast cancer survivors.
Conley CC; Rivera Rivera JN; Castro-Figueroa EM; Moreno L; Dutil J; García JD; Ricker C; Quinn GP; Soliman H; Vadaparampil ST
Transl Behav Med; 2022 Oct; 12(9):900-908. PubMed ID: 36205471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
